ASHM Report Back

Clinical posts from members and guests of the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) from various international medical and scientific conferences on HIV, AIDS, viral hepatitis, and sexual health.

Subscribe to this list via RSS Blog posts tagged in 2017 IAS Conference

The next session I attended was an industry sponsored session on Maturing Patients, Maturing therapy: Multidisciplinary management in HIV.  The session on management of Cancer in HIV by Christine Katlama (Professor of Infectious Diseases and Head of the HIV Clinical Research Unit
Department of Infectious Diseases France) & Jean-Philippe Spano (Professor in Medical Oncology, in the Department of Medical Oncology of Pr. David Khayat at the Pitié-Salpétrière Hospital in Paris, France) highlighted the increasing medical issue of people living with HIV and cancer diagnoses.  Amongst some interesting case studies, the main points discussed were that viral-induced cancers are more prevalent in HIV positive patients compared with HIV negative patients, the impact of smoking is excessive and needs addressing and multidisciplinary team approaches are extremely important to maximise the therapeutic management of HIV patients with cancers.

 

They demonstrated a great example of this collaboration in the form of a 6 weekly web-conference that they have set up in Paris between Oncologists, HIV specialists, pharmacists and immunologists where they discuss cases and ensure any possible treatment interactions between ART and chemotherapy are evaluated by experts as well as consideration of the possible benefits of new immune therapies. Whilst perhaps not the direct purpose of the session I found the take home message for me was thinking about the importance of cancer screening and prevention in the comorbidity assessments of stable HIV positive clients that nurses are increasingly involved with.  Smoking cessation should be continually encouraged and revisited at every possible occasion in a supportive way as unsurprisingly tobacco smoking is attributable to many of the cancers diagnosed.

 

 

Day 1 @ #EACS2017 did not disappoint!  Much like colourful displays of gelato in Milan’s exquisite restaurants the conference proved to be a veritable feast of tasty information and similar to the difficulty in picking your ice cream flavour so was the conundrum of choosing what session to attend!

 

 

 

To begin the day I started at the WAVE (Women Against Viruses in Europe) Workshop.  I listened to a very empowering speech given by Justyna Kopeć a Polish lady diagnosed with HIV 20 years ago who’s talk was entitled “The longest relationship I ever had”.  She highlighted at least 3 occasions when her diagnosis was missed between 1993 and 1997 which included participating in an anonymous HIV testing at university in which she did not collect her result, vising the gynaecologist with several recurrent vaginal infections and a GP visit for continued weight loss without dieting.  She talked about her journey of hope as new drugs came on the market at the time of her diagnoses, fear of dying, fear of treatment, fear of a daily routine, and trust in her doctors, trust in her family and friends and trust in science and in patient centred care.  She also talked about the changes over time for young women newly diagnosed in today's era in terms of pregnancy and living long enough to watch those children grow.  This session was a great reminder that HIV can affect anyone.  As a nurse I often see clients for HPV wart treatments and other symptoms such as vaginal candida and it reminded me of the importance of thinking of underlying reasons for persisting infections, accurate history taking (as people are transient between services and indeed countries) and not to overlook HIV as a possibility for someone who is not in the forefront of my mind as “high risk”.  Justyna closed with the statement “HIV testing should be a standard procedure among ALL sexually active people”.

 

Please also see the post from Emma Clements

Posted by on in Testing and Treatment

Sophie Flavell and John White spoke about STI testing and screening.

 

Important take home messages for me in this session were:

 

- don’t forget that for MSM with high risk behaviour Hep C is sexually transmitted ie make sure you include it in STI screen in high risk populations

- consider using doxycycline 200mg as a stat dose as PEP for chlamydia and syphilis (70% reduction in infections)

- pooled testing (3 samples in one pot)for chlamydia/gonorrhoea NAAT is currently not funded but saves money and will form part of the future in STI testing

Day 1, post number two.

This afternoon I attended a round table discussion on PrEP, after the opening ceremony. It seemed everyone in the conference was there as the room was packed! 

 

 

Rebecca Houghton will be blogging about this in more detail but I wanted to touch on the excellent presentation by Dr Emma Devitt from Dean Street Clinic in London as this was another analysis of a model of care, but of a single service. It is well known that the Dean Street model of care is progressive and hearing her discuss the way the service has actively adapted to the needs of the community in it's location, design, and flexible staffing is a lesson we should absorb. The clinic's redesign in 2014 to include an express service running 6 days a week is of note as it takes full advantage of many technologies that are available to us; videos explaining self-specimen collection that play within the mirror in the bathroom; and their GeneXpert has been calibrated to bypass a middle man and text clients their results directly. Inspiring stuff! She highlighted that express models still require medical staff on site to support nurses and health care assistants, and also discussed how the delivery of PrEP is evolving in their clinic with nurse prescribing. 

Hello from the 16th European AIDS conference in Milan. 

 

This morning I attended a very interesting workshop organised by WAVE, Women against Viruses in Europe, where numerous aspects of caring for women with HIV were presented and discussed.

 

The session started with a very powerful and insightful presentation by Justyna Kopec who has just celebrated her 20th anniversary of living with HIV. She discussed her journey to diagnosis and disclosed a number of lost opportunities to an earlier diagnosis (eg testing and then never returning for results) and highlighted that staff at her 'clinic' were integral to her feeling supported throughout her life living with HIV. This was a really excellent presentation to kick off with to remind us all to keep patients are at the centre of their care.  (see Catherine Orr’s notes from this session here)

 

Following was an analysis of the models of care for HIV positive Women in Europe split into West, Central and Eastern areas by Dr Annette Haberl from Germany, Dr Cristiana Oprea from Romania and Dr Inga Iatysheva from Russia, respectively. There is a huge amount of detail surrounding the variations in HIV care in each country and all face similar challenges in varying degrees i.e. coordination of allied specialist services such as gynaecology, psychology and social supports, or lack of integrated services, particularly in less economically enabled countries; barriers to accessing care surrounding child care responsibilities; lack of gender autonomy; fear of stigma. 

 

 

I noted that nurse led models of care for women living with HIV did not come up in discussion from any of the 3 speakers; the analysis may have not drilled down to this level but nurse led models of care could be useful in resource poor environments particularly. Additionally, further research as a high priority area was raised, and 2 speakers suggested that WAVE could be the right platform to assist coordinate research, exchange experience and create expert advisory groups. 

 

In day one of AVHEC17, we had been hearing presentations on how important the role of primary care workers would be in achieving the goal of elimination of viral hepatitis. Day two sessions gave us the opportunity to hear the stories of those who were leading the way.

 

 

The Rural Experience

First up was Dr Annie Balcomb, a rural GP based in Orange, NSW, who has been involved in Chronic hepatitis C treatment since 2008, and presented on The Rural Experience. Dr Balcomb described the structure around the Chronic hepatitis clinic she has run in recent years - a model working closely with gastroenterologists in a shared-case arrangement, that takes referrals from local GP's, nurses, health workers, drug and alcohol services, mental health services, forensics, hospital inpatients, gastroenterologists, and importantly patient self-referrals. The model has seen her successfully treat over 100 patients since the introduction of DAA's in March 2016. 

 

Over this time, Dr Balcomb has observed frequently the stigma and shame felt by many patients with chronic hepatitis C - some driving hundreds of kilometres to obtain their medications from a pharmacy where they could enjoy anonymity, others describing that some of the worst judgement and stigma they faced was within our own health-care systems. On the back of this, one of the central tenants to her ongoing work is the education and upskilling of GP's and other health professionals in her region, to optimise patient access to information and effective treatment. 

 

 

Dr Balcomb is also committed to being a voice that identifies and challenges some other barriers to access of care. She proposed a number of "ways forward" (see page 10 of Speaker Presentation PDF from her talk) to maintain patient safety while optimising access through primary care. Most exciting for me, were the use APRI<1 and FIB4 >2 as a fibroscan triage tool that has allowed some 60% of her cohort to proceed to treatment as non-cirrhotic without the need to obtain pre-treatment fibroscan; the hope of exploring options of shared GP care with gastroenterology input for some cirrhotic patients, using tools such as telehealth to improve rural access; and the excitement of pan-genotypic DAAs simplifying the treatment landscape for newcomers to the game. She instils the excitement of being involved in this area of medicine, and encourages us all to pass it along to our GP colleagues back home.

 

Challenges Ahead in Primary Care on the Path to Elimination

Next up, Dr Nicole Allard, a GP with special interest in hepatitis B and refugee health (who must be secretly cloning herself in order to continue her work as a medical epidemiologist at VIDRL, Melbourne health at the Doherty institute and PhD student at Melbourne University). She spoke on the Challenges ahead in primary care, and made a statement early in her talk that drew a few puzzled looks, and a lot of smiling nods - that "GP's are specialists - they specialise in primary care and in looking after people from marginalised populations". Recognising this, and both the challenges and advantages it presents, will go a long way towards engaging those Primary Care Specialists across Australia. When your speciality is primary care, the breadth of knowledge required is vast, so the message of who needs testing must be simplified - inclusion of screening messages in the RACGP Red Book will help this, as well as automatic cascade testing of HCV RNA and HBV DNA as indicated based on initial screening bloods, without the need for a specific request or re-bleed. She spoke of the power of creating a testing demand from patients, of reducing the stigma to allow these conversations to take place more readily in families, communities and consult rooms, and in providing support to GP's on the ground to best equip them to carry out testing and ongoing management effectively. She also raised the valuable tool of GP-to-GP referrals for those with colleagues with a special interest in viral hepatitis management. She addressed the tertiary specialists on the importance of good quality communication back to the GP, to enable effective ongoing monitoring in primary care and highlighting the role that a well written and relevant letter has in GP education (and as a heads up in case any non-GP specialists missed the memo: good communication including letters = more referrals + better overall care for your patients. Just thought that was worth repeating!)

 

 

Bridging the Prescriber Divide – Treatment Made Easy

Off the back of those two powerhouse primary care presentations, Professor Alex Thompson, the Director of Gastroenterology at St Vincent's Hospital, spoke on Bridging the Prescriber Divide: Treatment Made Easy, and the models being utilised in Victoria to achieve just this. He highlighted that Australia is among the first countries allowing and actively encouraging the treatment of hepatitis C by primary care doctors, and the responsibility we have to demonstrate that it is a safe and effective approach. He highlighted that the DAA treatments are generally well tolerated, but that practitioners need to recognise that symptoms such as fatigue, headache, insomnia and GI side effects can and do occur, and that despite these being far more acceptable compared to those suffered during previous treatment eras, we still need to counsel our patients in this regard. His "5 key questions" in the approach to treatment work-up, represent a straightforward approach that is easy to follow (See: Speaker Presentation PDF page 9: The KISS principle; Is Cirrhosis Present; Who needs to see a specialist on page 13).

 

Prof Thompson also spend some time discussing the approach undertaken by the Eliminate Hepatitis C (EC) Partnership, which aims to "support and enhance programs to increase HCV treatment update among people who inject drugs, using nurse-led models of care in community and prison settings" and to "assess the feasibility and impact of treating high enough proportions of PWID to reduce new infections and inform HCV elimination models in Australia and globally". It's great to see the diversity of approaches being undertaken in trying to engage at-risk communities. See their implementation plan via page 16 on the Speaker Presentation PDF.

 

Eliminating Hepatitis C - The Cairns Experience

The final speaker for the morning, Associate Professor Darren Russell, is a sexual health physician and the Director of the Cairns Sexual Health service who spoke passionately about Eliminating Hepatitis C - The Cairns Experience. He recalls a meeting held in their department, the morning after the initial DAA's were PBS-listed in March 2016. The strategy was to identify and work with priority groups, with the plan to "Hit 'em hard, hit 'em early", ramp up quickly and clear the warehouse. Local liver clinics triaged back to GP's, with waitlists then cleared in just a few months. The Sexual Health Service adopted a same-day assessment and treatment clinic, that utilised on-site pathology and fibroscan with links to local pharmacies to ensure medications were kept on the shelves and therefore available for supply without delay. By working with community groups including Cairns Hepatitis Action Team (CHAT), media interest was stoked, prompting a dialogue in the community and firing up demand for testing and treatment in at-risk groups. Health professionals in prisons, ATODS, Aboriginal Medical Services, Rural and remote, and General Practice settings were supported with onsite ASHM training to equip them to respond to this demand, with liver and sexual health clinic support via phone/email/fax, and "academic detailing" where GP clinics who were interested but not yet prescribing received outreach support and training. This multi-pronged approach has led to the enviable situation, where Cairns can say that "virtually all the people in Cairns and surrounds - and further North - who know they have hepatitis C and want treatment, have been treated" with the focus now on increasing testing, finding the undiagnosed cases especially in those clients connected with mental health services and young injectors, and watching for incident cases in particular in prisons and Indigenous communities. It was an exciting demonstration of how a concerted whole of system approach, utilising resources including primary care and community groups, can lead to impressive results.

 

 

 

 

The Panel Discussion

The follow-up panel discussion was engaging and energising - it left me with a number of messages, first and foremost that Peer-to-peer GP education is key to getting the message out there. So I'll start with this blog, my local practice and GP and nursing colleagues, the Australia and NZ-wide community of GP's DownUnder and my at-risk patients. I'd encourage you to start a conversation too - with friends, family, colleagues - stamp the stigma and get word out that treatment is available... or better yet, sign up for some ASHM training and get testing and prescribing. It's not often in GP you get to say "You're cured" - let's give as many people as possible the opportunity!

 

 

See selected speaker presentations from this session, including:

I attended the Australasian Viral Hepatitis Elimination Conference as a GP hepatitis B prescriber in an AMS (Aboriginal Medical Service), so my particular interest was to find out how we are doing in the rural and indigenous sectors and to get ideas as to how we might improve our services.

In this regard the Northern Territory is above the national average of treated Hep C patients at around 17%. My practice seems more inclined toward identification and adequate surveillance of hepatitis B (already a massive task). One factor in this is the medicare payment of only 3 hepatitis tests at any one time, leading to less than satisfactory levels of hepatitis C antibody checks. However, I suspect infection rates are low with respect to hepatitis B, due to lower use of IV drugs in the rural indigenous setting.

However, if the above holds, one wonders if rates of hepatitis C in indigenous communities may not be higher than the (rising) age standardised rates presented by Prof Rebecca Guy in her presentation.

If there is one thing I would hope to improve having attended this conference, is awareness and testing for hepatitis C in my AMS.

On a global front, it was disappointing to hear data from Homie Razavi (Managing Director of Center for Disease Analysis) that we [Australia] may be falling short of the 5 million hepatitis C treatments necessary annually to achieve elimination by 2030, even if total numbers of cases are declining.

Homie pointed out that shortcomings include restriction on treatment of young patients and (worldwide) lack of primary care involvement. However, a major factor is lack of political will, as evidenced by the failure – to date – of the pooled procurement initiative. While Homie pointed out that individual countries may negotiate their own prices on hepatitis treatments, it is unlikely that they could negotiate the prices achievable through large, multinational orders (with cash changing hands through secure banking transactions to ensure transparency).

Ed Gane (Heptatologist at Auckland City Hospital) presented a succinct account of the challenges NZ faces in eradicating hepatitis C and how it is going about it.

The challenges are:

  • the still rising rates of infection (probably similar to rural NT)
  • the numbers of still undiagnosed patients and treatment uptake already falling (pool of "accessible" patients running out).

Solutions proposed include increased GP prescribing (33% of scripts vs almost none in 2015), pangenotypic treatment régimes and targetted testing.

 

I suggest that GP prescribing for hepatitis (and other "shameful" diseases such as HIV) has benefits beyond than just "increasing coverage". Patients are more likely to come for, and accept testing. Treatment proposed by a trusted GP is more likely to be understood and followed, than if prescribed by a specialist that they meet on 1 or 2 occasions (Note: I don't wish to belittle highly-skilled and caring clinicians, who often understand very well the complexities of care in an indigenous setting). No doubt this applies in the general population – and maybe even in NZ.

 

See selected speaker presentations from this session, including:

 

The Australasian Viral Hepatitis Elimination Conference 2017 held in Cairns was a an eye opener for me. I was intrigued by the international efforts to try and meet the WHO target to eliminate Hepatitis B and C by 2030. The revolution of treatment of Hepatitis C with DAAs which have high cure rates with fewer side effects should make this possible. However, the message was clear, to meet this target globally, efforts should not be at the local national level only, the international scene needs to be the focus.

Professor Samuel So, director of the Asian Liver Centre presented a great example of one of the ways this could be done in the Keynote 3 session, JoinJade: A Culturally and Linguistically Tailored Campaign to Help End Hepatitis B. His centre is targeting the Asian community with higher prevalence of Hepatitis B both in the US and in Asia.
View his presentation
here.

 

In plenary 4, Dr Homie Razavi, managing director CDA, also demonstrated international efforts with provision of epidemiology data and the Global Procurement Fund. He highlighted the challenges faced in trying to make this possible globally with no country signing up to the procurement fund which should make the DAAs more affordable, especially for poorer countries with higher rates of Hepatitis C infection.
View his presentation here.

 

Locally, here in Australia, the gap between the indigenous community and the rest of the community in Australia is just as wide for hepatitis infection. The rates of Hepatitis B and C are significantly higher among the indigenous population. There was discussion of formulating policies and programs targeting the indigenous community, including formal and non-formal or "cowboy" methods to improve access and treatment for this community.

Working for the Aboriginal and Torres Straight Islander community health service in Brisbane, this is important for me as a take home message. I can't wait to get back to work and start implementing the knowledge I acquired! I also hope to take this information back to my country of origin Zambia, my bit of effort in trying to eliminate Hepatitis globally.

 

A/Prof Rebecca Guy, Head of Surveillance, Education and Research Program, Kirby Institute UNSW, Australia, discussed the importance of Epidemiology and measuring our response at an Australian national level as we strive towards the WHO Hepatitis B and Hepatitis C targets.

She highlighted parts of the tracking process using examples of data from various specific population groups. The HCV prevalence of participants from NSP is around 55%, the highest incident in any group, with only 50% reporting a HCV test in the previous 12 month period. Of particular concern is the number of <25 year olds with HCV notifications that had not declined but remained at 15%. A measure of risk behaviour showed the incidence of needle/syringe sharing in the past month amongst people who inject drugs is around 15%.

We were reminded of the importance of our task as the number of people suffering from severe complications of HCV infection (cirrhosis/ hematoma/ death) continues to increase gradually.

Australia has made a dramatic response to the availability of DAAs by treating over 30,000 HCV in 2016, though our response needs to be sustained at more moderate levels in order to achieve Elimination of HCV in our nation by 2030.

With regards to HBV the incidence of notifications in young people < 24 continues to decline, likely to be a result of our Hep B childhood vaccination program. However, the HBV Diagnosis and care cascade continues to lag behind that of HCV.

In the Epidemiology sense, WHO targets currently set are defined as "elimination as a public health problem" rather than eradication (reduction of the world wide incidence to zero) or elimination in its stricter sense (cessation of transmission of a disease in a single country).

There are a number of ways of tracking progress towards elimination of HCV as a PHP.

 

 

  1. Modelling showed that while the number of new patients initiated on DAA will decline after the warehouse effect has passed, the WHO targets can be achieved before 2030 by intermediate estimates.
  2. Data at a finer geographical level showed widely differing treatment levels of both Hep B and Hep C across geographic regions of Australia and the need for targeted action in geographic locations.
  3. Collection and feedback of health service delivery data to individual sites or groups of services provides valuable insight and highlight specific needs and facilitate tailored management.
  4. Identify and overcome various barriers to accessing prevention services
  5. Importance of measuring new cases of HCV infection using HCV RNA testing as well as HCV antibody testing.
  6. Improve the completeness of Indigenous data.

 

 

 

 

 

 

A key part of this is the use of "data linkage" where information from all sources of hepatitis C related data are fed back to a central HCV notification centre to facilitate research analysis.

 

It is vital that we collect and feedback this data to the various local, state and National organisations for future Hepatitis Elimination management in Australia.

 

See also selected speaker presentations from this session, including:

Plenary session #5 was an inspiring reminder not to forget the people who are at the centre of why we do what we do. 

Rhondda Lewis, viral hepatitis health practitioner with Cairns Sexual Health Service and Yvonne Drazic started the session, speaking about their involvement with the Cairns Hepatitis Action Team (CHAT).   CHAT was established in 2013 by peers to empower patients to be the lobbyists and agents of change in the area of viral hepatitis. 

Through Asset Based Community Development, focusing on peers’ strengths and abilities to explore the community’s needs and visions for the future, the group has been very successful in organising many large events and contributing to the goal of having Cairns “Hep C free by 2020”. 

They have tried to avoid using the word “problem” when referring to viral hepatitis to reduce further potential for stigma and discrimination.  Instead, they focus on resilience, peer support, learning from others and increasing confidence to empower and promote real engagement to improve health efficacy.   They are rightly proud of CHAT reflecting Ottawa Charter principles in a real world setting. (1)

See Rhondda and Yvonne's presentation here. 

A/Prof Phillip J Mills, Kulkulgal Tribal Elder of Zenadth Kes and Associate professor with the Australia Institute of Tropical Health and Medicine (JCU) followed with a talk rallying us to press for policy change when it comes to how we manage the Aboriginal and Torres Strait Islander population who are affected by viral hepatitis.  He made excellent points that we should ensure that our services are culturally appropriate and consider the whole journey for the patient and the impact of various social determinants of health, rather than managing the disease in isolation.  He challenged us to consider that the language we use can come across as demeaning and damage the therapeutic relationship, thus affecting engagement in care.

Lastly, Melanie Walker, the CEO of the Australian Injecting and Illicit Drug Users League (AIVL) presented 3 case studies demonstrating the impact Hepatitis C can have on families.   She also pointed out to us that while 29,160 people with hepatitis C were cured in 2016, 5,900 new infections occurred over the same time period. 

If we want to reach the target of elimination of Hepatitis C by 2030, prevention and harm reduction need to be our focus, as well as considering how to assist those who are less well connected to the health care system to access treatment.  

Melanie discussed some of the barriers being no Needle and Syringe programs (NSP) in prisons, no formal recognition or funding of peer workers, punitive measures targeting people who inject drugs (PWID), stigma and reduced access to health services in regional Australia.   

In addressing these issues, AIVL’s work over 2017-2018 will focus on enhancing NSP service outcomes, building capacity amongst peer educators and other health professionals, improving Hep C outcomes for people exiting custodial care to improve transition to primary care, developing resources directed at harm reduction in the ATSI and CALD communities, creating a new website and continuing to write national policy papers to improve health outcomes in PWID.

These impressive goals have the potential to make real improvements to the health and well-being of the lives of PWID, as well as contributing substantially towards Australia’s elimination target.

See Melanie's presentation here

 

1. Lewis, RM, Drazic Y, Engaging community: The Cairns Hepatitis Action Team – paths to patient involvement, Journal of Virus Eradication Vol3, sup 2, August 2017

 

 

Professor Rebecca Guy (Program Head and Professor, the Kirby Institute UNSW) gave a very illuminating presentation on the epidemiological mechanics of elimination programs and the areas that will need to be focused on if Australia is to achieve elimination of hepatitis C as a public health problem.

These areas were outlined as Modelling, Obtaining data at a finer geographical level, Developing better health service delivery data, Understanding barriers to assessing services, Monitoring of new cases and Improving completeness of indigenous data.

Of particular interest was the need to understand where new cases are coming from as this will help identify where our prevention strategies are failing and where we need to focus our efforts.

Notification of RNA data was suggested as a way for better identification of new cases.

Read more about other speaker presentations in this AVHEC17 session

 

In this presentation, Dr Nicole Allard describes a research project to examine whether an intensive follow-up and recall system improved liver cancer surveillance programs in patients with chronic hepatitis B.  On the basis of current recommendations for 6-8 monthly liver ultrasounds and AFPs, optimal screening was defined as having achieved 2 scans every 14 months, sub-optimal screening as one scan every 14 months and poor screening as less than one scan every 14 months.

The intervention consisted of nurses conducting an audit to detect patients requiring HCC surveillance within the clinic patient base, upskilling the healthcare workers in hepatitis B management, and establishing a proactive recall system consisting of a variety of strategies such as calling of patients, sending out of path forms by mail or sending out pre-appointment confirmation texts.

A participation rate of 75% was obtained in this patient cohort yet optimal screening was only achieved in 25% of patients. It was not clear what the baseline of adherence to screening schedules were like prior to the intervention, and thus it is difficult to interpret this result.

An important observation made during this study was that patients often had little understanding of their individual risk of HCC, and that this perhaps impacted on their adherence to screening schedules.

Recommendations included developing a low English literacy tool to help to explain this better to patients, implementing a community awareness program, considering the role of a liver cancer registry, and supporting the development of a more feasible method of screening.

See Nicole's presentation here 

This session at the 2017 Australasian Viral Hepatitis Elimination Conference was a series of oral abstract presentations exploring a wide range of strategies in engaging marginalised populations, including persons incarcerated, people who inject drugs (PWID), Aboriginal and Torres Strait Islander populations/communities, and Culturally and Linguistically Diverse (CaLD) populations. Subsequently, various models-of-care adopted for each population in their respective studies and community settings.

Prof Andrew Lloyd provided an overview of the care for HCV affected people in prisons in Australia. Among the total of 230K living with chronic HCV in Australia, 65k of those are persons incarcerated, with many of this cohort being PWID and/or undertaking opioid substitution therapy (OST). Prof Lloyd spoke of the challenges of treatment adherence given the frequently movement of prisoners from one area of the prison to another (or movement to other facilities) and in some cases relatively short stays. The Surveillance and Treatment of Prisoners with Hepatitis C (STOP-C) study that he leads via the Kirby Institute throutout prisons in NSW is a nurse-led model of hepatitis care (NLMC) are appears to be very effective: a 95% of treated/assessed rate and currently 100 cases treated per month, despite barriers of pharmacy technology, challenges in drug procurement, etc. Future directions in this study include: establishing an Australian national prisons hepatitis network; to implement a practical strategies, such as, a one-stop shop for testing and treatment, and a 'treatment-as -prevention' approach aiming to eliminate hepatgitis C from the prison sector.

 

Dr Phillip Read of the Kirketon Road Centre (KRC) Sydney, presented a model-of-care for Alcohol and other Drugs (AoD) clients engaging with a huge diversity of care providers. There are numerous non-medical services ranging from government services to NGO and religious-organisations contributing to the complex care model for AOD clients, offering a range of services beyond clinical treatment, such as counselling. Currently, it is estimated that at least 25K PWID living with hepatitis C are still needed to be treated. The possible solution to engage PWID populations is to use an OST infrastructure. There is, however, a few challenge facing this strategy. For example: methamphetamine IV users have less medical contact, with only 10% of them are in care. Patients often had poor venous access, poor adherence and high risk for reinfections. Furthermore, many patient’s relationships with AoD services may not be always harmonious - with many experiencing stigma and discrimination in these settings. Nevertheless, many can be tackled in AoD-specialised setting. For example, HCV RNA testing using dried blood spot will be very practical for PWID with poor venous access. Overall, the HCV elimination campaign will be benefit from co-working with peers in the model of care for AOD. 

Ms Carla Gorton and Ms Kathy Clark from Cairns Sexual Health Service in Queensland shared a personal experience of approaching and engaging with HCV in a sexual health setting/context. Their key messages were very strong: Respect, dignity, individualised care were required in providing care according to the individual’s need. Ms Gorton shared strategies for providing care for the sensitive group of people, including sexual worker and transgendered persons. Ms Kathy Clark provided contact, encouragement and transport to care. Personal engagement also helps to address issues such as shame and guilt and life priority. To reach people’s heart and mind, the networking of Cairns community members has facilitated a friendly access for hepatitis C patient to reach treatment without restriction.

Dr Malcolm McDonald is a consultant physician serving in three Indigenous health services in Far North Queensland. He shared in his presentation his plentiful experiences and great insight in approaching indigenous people in rural and remote communities. Each community has a unique history and different setting. Health Service should be in the community. It is encouraging to see that readily in-community care is available, including testing and treatment, even the in-community Fibroscan.  

 

The end panel discussion of this session emphasised the need of continuing care and information should be transferred to primary carer, as well as, the barriers of providing continuing care for these populations.

Access speaker presentations mentioned via the AVHEC website

 

A/Prof Ben Cowie's plenary talk at AVHEC17 on the Australian Progress and challenges in Hep B was highly engaging and it is certainly true that the migration laws in Australia have been discriminatory with regards to hep B patients who may be rejected for a permanent residency.

 

He also highlighted the importance of testing people from high risk countries and Indigenous background, and stressed the role of primary care practitioners who are at the forefront and are in the best position to identify who needs monitoring and who needs treatment.   

 

Another issue he mentioned with regards to GPs who have patients with chronic hep b but are untreated or maybe under monitored is the possibility of litigation down the track if these patients develop cirrhosis or cancer. It is an important issue that might just be one of the things that can drive uninterested GPs to increase their awareness and treatment of this chronic disease. 

 

Link to Ben Cowie's speaker presentation here

 

 

The global impact of chronic HBV cannot be underestimated, with 257 million people affected. More people die from chronic HBV compared to HIV/AIDS or malaria.  

 

Dr. Samuel So has launched a world-wide campaign with JoinJade, which aims to educate and engage people in the community, to increase awareness in order to achieve elimination of hepatitis B and thereby decreasing mortality and morbidity. 

 

The goal is to eliminate hepatitis B and C by 2030, and although this sounds ambitious, it is not impossible.  He recommended engagement of the government to coordinate stakeholders including the criminal justice systems to treat correctional facility inmates, professional organizations to treat patients in primary care and the CDC and local health departments.   

 

In the US, Asians and Pacific Islanders make up 6% of the US population, and these groups make up more than 60% of chronic HBV in the US.  In Australia, we see an increasing number of migrants from endemic countries and in the NT, most cases of CHB are made up of Indigenous and the CALD community.   

 

He initiated the campaign in Qinghai, China and this led to the Chinese government adapting a national vaccination program for hep B, and his efforts should be lauded.

  

His Jade Ribbon campaign has reached Australian shores, and hopefully this will lead to a better community engagement with regards to awareness, as well as better primary care involvement in identifying and treating patients with CHB. 

His talk ended with a video of Jackie Chan encouraging people to get tested and treated.

 

Link through to Prof Samuel So's speaker presentation here

 

JoinJade: Access the campaign here

 

The Australian Viral Hepatitis Elimination Conference 2017 is aimed at equipping medical practitioners with strategies to achieve this goal by the next decade.The conference has used key note speakers from around the world to deliver these strategies.

In one of the sessions titled Poster walk: DAA treatment therapies, we reviewed several recent research articles with results that, when fully implemented, will enhance the elimination of viral hepatitis in Australia.

One of the research articles we reviewed was titled: High SVR rates with eight and twelve weeks of pangenotypic Glecaprevir/Pibrentasvir: integrated efficacy and safety analysis of genotype 1-6 patients without cirrhosis.

In this presentation, we learnt that a new medication for the treatment of hepatitis C is being registered in Australia very soon. It is highly effective against all genotypes, so no genotype testing is necessary; a cost saving measure. It is also highly effective in 8 weeks, again a cost saving measure and a boost for compliance.

It can be used in renal impairment and has very few drug interactions. I am fascinated with this new medication because it would be suitable for many of my patients with compliance problems, renal problems and who are on many medications with possibilities of drug interactions with anti retroviral medications.

I have no bias or interest with any drug company. My interest is with what will enhance the elimination of viral hepatitis in Australia.

Access various Posters for DAA Treatment Therapies from AVHEC17 here

I am reporting from oral abstracts being presented at AVHEC17 regarding understanding the epidemics (modelling and surveillence).

 

The first talk , presented by Dr B Hajarizadeh (Kirby Institute, UNSW Sydney) , outlined results of Surveillance and Treatment of Prisoners with Hepatitis C (SToP-C) in New South Wales. This study was conducted in 4 prisons and revealed high HCV incidence in residents. It was confirmed that in almost all cases HCV transmission was primarily associated with intravenous drugs use. Prisoners almost always share needles so reinfection levels are twice higher than for primary infection. This study concludes the importance of introduction of wide preventive strategies including treatment as the very important part of prevention. 

 

Jenny Iversen (Kirby Institute, UNSW Sydney) stressed the importance to monitor progress towards elimination of Hepatitis C infection in Australia. The Australian Needle Syringe Program Survey (ANSPS) examined treatment within PWID over the last 5 years to ensure quality of care . The study included self-completed questionnaire and dried blood spots serological testing.  Associated factors (like age, gender, geographic location, frequency of drugs injections etc.) were also included in the study. This study was demonstrated high involvement of PWID with Hepatitis C infection after introduction of DAA under PBS. Further plans include recommendations for the RNA testing to confirm spontaneous and treatment induced clearance. 

 

Amy Kwon (Kirby Institute, UNSW Sydney) presented Part of BBV & STI Research, Intervention and Strategic Evaluation Program hold in Australia to assess level of DAA required to eliminate Hepatitis C by 2030. Using mathematical model and three possible scenarios (optimistic, pessimistic and intermediate), it was concluded that Australia finally will meet the WHO HCV elimination targets in 10-13 years. Australia invests around 1 billion dollars (2016-2020) in elimination program without restrictions on stages of Liver disease. The treatment mostly includes DAA with no Interferons; re-treatment is also allowed. Some limitations – like internal migration or reinfections – were also taken into consideration, however would not have crucial influence on the process of elimination. 

 

Recommendations for HCV testing were presented in a talk by Dr Nick Scott from Burnet Institute. He focused on models of care, treatment scale-up and care cascade among people who injects drugs in Australia. The suggestion was given for the additional testing (PCR test) to the HCV RNA. Effectiveness of such combination was confirmed statistically along with annual frequency of the testing. Such improvements in the testing system will make possible to achieve the WHO elimination target and minimize the likelihood of future outbreaks. 

 

Kelly Hoskins (Continuous Quality Improvement Facilitator, Northern Territory Government) presented data about Hepatitis B infection in the Indigenous populations. The prevalence of HBV infection within Aboriginal community is much higher (up to 12%) than in general Australian population (1%).  The project targeted on identification of those who are chronically infected and who never undergone HBV testing. The process was piloted in 5 Aboriginal communities and involved data collection and testing. The part of the project was also created (pointed?) to increase educational opportunity for the GP and other primary care providers for the proper Hepatitis B care with big attention  to find all Chronic Hep B clients and engage them to the care.  

 

Ms Maryam Alavi (Research AssociateKirby Institute, UNSW Sydney) talked about the 

burden of liver disease and comorbidities within PWID. The study revealed the importance of continuing to increase access to screening, care and treatment for individuals affected .  

 

The final presentation by Karen McCulloch (Research FellowUniversity Of Melbourne) 

characterized populations with Hepatitis C to improve access to antiviral therapy programs. This study evaluated comorbidities and other characteristics of people who are current PWID and non-PWID in NSW. The higher rate of comorbidities was reported in people with HCV infection so longer hospitalization was usually needed in case of inpatient care.

 

Link through to oral abstracts and speaker presentations here

The presentation by Professor Dore was a rapid but detailed overview of the situation of the current situation with Hepatitis C and how things have progressed over the past two years with the introduction of the Direct Acting Antiviral drugs since 2015, and more particularly, the subsidisation of these medications on the Australian Pharmaceutical Benefits Scheme in March 2016.

Professor Dore is the head of the Viral Hepatitis Research Program at the Kirby Institute at the University of New South Wales, and an Infectious Diseases Physician at St Vincent’s Hospital in Sydney.

The Real world efficacy of antiviral therapy in chronic hepatitis C (REACH-C) in Australia research report is published by his team.

He emphasised the impact of these medications as safe, effective and well tolerated drugs, in contrast to those previously available. The availability of these drugs almost without restriction to eligible patients has made a major impact on both and individual and population level. With almost a quarter of a million patients in Australia living with Hep C, knowingly or otherwise, the possibility of eliminating Hep C as a major public health issue in Australia is an achievable aim by 2026 to 2030.

Over 32,000 people were treated between March and December in 2016, representing 14% of those effected. However, figures for 2017 show declining numbers being treated compared to last year. The figures are still encouraging for people in “at risk” groups including this with Cirrhosis and those who inject drugs, and post treatment follow-up requires enhanced efforts.

Professor Dore went on to compared the “real world efficacy” of the DAAs in various situations and spoke of the REACH-C trial observational cohort, and compared the different efficacies of the different DAA regimes, and genotypes of Hep C. Various diverse models of care delivery in different situations were then discussed. Modelling of Hep C elimination in different scenarios (Pessimistic, intermediate, and optimistic) were given.

In summary, it was concluded that: Australia is leading the world in treating Hep C with DAAs, key populations for the elimination of Hep C are being reached, outcomes are favourable despite some failures in followup, and to reach the goals set by WHO, bradened models of treatment delivery are required over the next two to three years.

Professor Dore is Head, Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW, Sydney Australia, and Infectious Diseases Physician, St Vincent’s Hospital, Sydney, Australia. He has been involved in viral hepatitis and HIV epidemiological and clinical research, clinical care and public health policy for 20 years.

Access Prof Greg Dore's speaker presentation here

 

 

This session was focused on the "whole system approach" and working together to deliver care to people living with HCV.

HCV affects more than 250,000 Australians resulting in up to 630 deaths from liver cancer and liver failure each year. Globally, more than 500,000 people die from HCV related causes. How can we work together with research organisation, policy makers, primary care providers, community and affected populations to change the course of HCV infection and its impact as a public health threats?

The speaker, Dr Jacqui Richmond, gave us a fantastic introduction to motivate me as a primary care provider to manage HCV in my general practice setting. In the past, there were not many primary care practitioners who wanted to be involved in HCV care in the community due to multi-factorial barriers and lack of clinical infrastructure.

With the advent of well-tolerated, short duration, interferon free DAA therapy, there is an opportunity to increase accessibility to treatment by providing care in the community setting.

Jacqui gave us very informative talk about how to deliver health services to people living with hepatitis C. Hepatitis C elimination will not occur without a whole of system approach. Elimination will not occur without GPs, nurses,community-based workers, peer workers, pharmacists, aboriginal health workers and CALD workers. Our implementation plan is to utilise a health system framework to increase demand through health promotion, increase clinical capacity through training and education, streamline clinical pathways to increase access to hepatitis C testing & treatment in the community & prison settings, establish integrated HCV prevalence and incidence over time, pilot and evaluate new interventions to increase uptake of HCV testing & treatment.

Many hands make light work. A partnership approach is the only solution. We are at the beginning of a long journey, hepatitis C is not going to be prioritised by every health professional po. We are competing for the attention of health professionals against well-resourced diseases and organisations. TOGETHER we are stronger.

Link through to Jacqui's presentation here.

Fantastic final lecture of the day at the 2017 Australasian Viral Elimination Conference! Dr Jacqui Richmond really nailed it when she said that we will not eliminate hepatitis C without a whole of system approach. A very insightful lecture into the challenges in educating the workforce and the reasons why there has been such a slow uptake of new knowledge into practice. To move DAA prescribing into the community is the essential next phase towards elimination, but this will require a change in practice on the part of GPs. Jacqui used the diffusion of innovation theory to explain how this change might happen. A very thought provoking lecture.

Jacqui Richmond has worked in viral hepatitis for the last 20 years in nursing, education, research, and policy development. Jacqui currently works at the Burnet Institute, Melbourne Health and La Trobe University, where the broad focus of her work is on building the capacity of the health professional workforce to test, treat and manage the health care needs of people living with viral hepatitis.

Link to Jacqui Richmond's speaker presentation here

 

Link 

The Multicultural HIV and Hepatitis Service (MHAHS) has launched a multilingual communication communication toolkit… https://t.co/eXa72MaSv2

ASHM ASHM

#ASHMResource HIV Management in Australasia is a ‘living resource’ for health practitioners managing people with HI… https://t.co/yKj1D4aCrE

ASHM ASHM